The TEL-AML1 fusion gene results from a chromosomal translocation t(12;21)(p13;q22), which is one of the most frequently observed genetic abnormalities in childhood B-lineage Acute Lymphoblastic Leukemia (ALL). Identifying this fusion gene not only confirms the diagnosis but also provides valuable prognostic information, helping clinicians tailor treatment strategies to individual patients. Accurate detection of the TEL-AML1 fusion gene supports early diagnosis and improved clinical evaluation, enabling faster, evidence-based clinical decisions and better long-term outcomes for patients.
To address this important clinical need, Genes2Me introduces the AML1 Fusion Real-Time PCR Kit — an advanced in vitro diagnostic solution designed for the rapid and accurate detection of the TEL-AML1 fusion gene in clinical samples. Built on highly sensitive Real-Time PCR technology, the assay enables reliable molecular detection to support leukemia diagnosis, prognosis, and patient management.
The AML1 Fusion Kit utilises a multiplex Real-Time PCR system incorporating custom primers and fluorescent probes targeting TEL-AML1 fusion sequences. FAM-labeled probes enable detection of the TEL-AML1 fusion gene, while HEX-labeled probes simultaneously detect an internal control (RNase P) within a separate channel. This built-in control validates both sample quality and workflow accuracy, minimising the risk of false-negative results and enhancing overall test reliability. The multiplexing capability enables simultaneous detection of multiple targets within a single reaction, making the process more efficient and resource-friendly.
TEL-AML1 fusion gene testing plays a vital role in the early diagnosis and prognosis of Acute Lymphoblastic Leukemia (ALL), making it particularly significant in pediatric oncology where timely intervention can greatly improve patient outcomes. Early and accurate detection helps clinicians not only confirm the diagnosis but also assess prognosis and guide treatment planning. With detection at Ct ≤ 35, the AML1 Fusion Kit provides laboratories with dependable molecular diagnostic performance for leukemia detection and disease management.
Specifically detects TEL-AML1 fusion gene sequences associated with childhood B-lineage ALL.
Reliable detection at Ct ≤ 35, ensuring confident and reproducible results.
Simultaneous detection of TEL-AML1 fusion gene and internal control (RNase P) for enhanced assay reliability.
Validated on leading Real-Time PCR platforms including Thermo Fisher QuantStudio™ 5, Bio-Rad CFX96, Roche LightCycler® 480, and Genes2Me RapiCycler 96.
Rapid turnaround provides timely and reproducible data for critical decision-making.
Easy reaction setup and optimised amplification protocol for efficient laboratory testing.
With the AML1 Fusion Real-Time PCR Kit, laboratories can achieve highly sensitive, reproducible, and clinically meaningful detection of the TEL-AML1 fusion gene. By supporting early diagnosis and improved clinical evaluation of leukemia, the kit helps clinicians make informed decisions for patient care and disease management. Empower your laboratory with the AML1 Fusion Real-Time PCR Kit — because timely molecular insights can make a lasting difference in patient outcomes.
AML1 Fusion Real Time PCR specific amplification plot of Treponema pallidum Positive Control (HEX Channel) along with Internal Control (Cy5 Channel)
| Commercial Name | Old Cat No. | New Cat No. | Pack Size |
|---|---|---|---|
| AML1 Fusion Real-Time PCR Kit | G610047-1 | G610032-1 | 50 Tests |
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
© 2025 Genes2me. All rights reserved.
